Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas

CCI-779 (temsirolimus), an ester of rapamycin and an inhibitor of the mammalian target of rapamycin (mTOR), is currently in phase II trials for treatment of patients with solid cancers. The mTOR functions as a checkpoint for cell proliferation, with upstream Akt and downstream p70S6K serving as its...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of clinical and laboratory science 2006, Vol.36 (3), p.283-293
Hauptverfasser: Lin, Fan, Zhang, Ping L, Yang, Ximing J, Prichard, Jeffrey W, Lun, Mingyue, Brown, Robert E
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 293
container_issue 3
container_start_page 283
container_title Annals of clinical and laboratory science
container_volume 36
creator Lin, Fan
Zhang, Ping L
Yang, Ximing J
Prichard, Jeffrey W
Lun, Mingyue
Brown, Robert E
description CCI-779 (temsirolimus), an ester of rapamycin and an inhibitor of the mammalian target of rapamycin (mTOR), is currently in phase II trials for treatment of patients with solid cancers. The mTOR functions as a checkpoint for cell proliferation, with upstream Akt and downstream p70S6K serving as its most important mediators. The aim of this study was to evaluate the expression and activation of the Akt-mTOR-p70S6K pathway in renal cell carcinoma (RCC), seeking to strengthen the rationale for targeted therapy of RCC using rapamycin or a rapamycin analogue. Tissue microarray sections containing 128 primary RCCs, 22 metastatic RCCs, and 24 non-neoplastic (normal) kidneys (NK) were immunostained with monoclonal antibodies to phosphorylated (p)-Akt (Ser473), p-mTOR (Ser2448), and p-p70S6K (Thr389). Western blotting was performed on 3 cases of clear cell RCC (CRCC) and the corresponding non-neoplastic (normal) renal tissues using the same antibodies. The immunostain scoring system included: (a) location; (b) distribution; and (c) intensity. The normal kidneys provided baseline scores for comparison. Expression of p-Akt, p-mTOR, and p-p70S6K was seen in 100% (n = 24) of NKs and nearly 100% (n = 150) of both primary and metastatic RCCs. The p-p70S6K was located in the nucleus in both NKs and RCCs. The p-Akt was observed in the nucleus and cytoplasm of NKs and in the nucleus and cytoplasm/ membrane (plasmalemma) of RCCs. The p-mTOR was identified in the membrane of NKs and the membrane/nucleus of RCCs. The levels of expression of p-p70S6K, p-mTOR, and p-Akt were significantly higher in RCC than in NK in the overall pattern (intensity and distribution, p
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_68813780</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68813780</sourcerecordid><originalsourceid>FETCH-LOGICAL-h239t-db27e71992ea2ef889cac10ae18483861a8f1a91220c1586ece9b1b2eb29eb5d3</originalsourceid><addsrcrecordid>eNo1kMtOwzAQRb0A0VL4BeQVu0i287KXqOIlFVVCZR2NnYkaFNvBdgr9ewKUzR3NnaPRzD0jS8YUz-q8ZgtyGeM7Y0IVBbsgC16pkotKLUl48WHc-zH4hN72hoJrqfUDmmmAQI13ZrYTuBSp7-Yp9QcM-DUGjBHbXxxM6g-Q5s7utq90hLT_hCPtHQ3oYKAGh1kgmN55C_GKnHcwRLw-1RV5e7jfrZ-yzfbxeX23yfYiVylrtaix5koJBIGdlMqA4QyQy0LmsuIgOw6KC8EML2WFBpXmWqAWCnXZ5ity-7d3fu5jwpga28efW8Chn2JTScnzWrIZvDmBk7bYNmPoLYRj859S_g1Sx2VK</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68813780</pqid></control><display><type>article</type><title>Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Journals@Ovid Complete</source><creator>Lin, Fan ; Zhang, Ping L ; Yang, Ximing J ; Prichard, Jeffrey W ; Lun, Mingyue ; Brown, Robert E</creator><creatorcontrib>Lin, Fan ; Zhang, Ping L ; Yang, Ximing J ; Prichard, Jeffrey W ; Lun, Mingyue ; Brown, Robert E</creatorcontrib><description>CCI-779 (temsirolimus), an ester of rapamycin and an inhibitor of the mammalian target of rapamycin (mTOR), is currently in phase II trials for treatment of patients with solid cancers. The mTOR functions as a checkpoint for cell proliferation, with upstream Akt and downstream p70S6K serving as its most important mediators. The aim of this study was to evaluate the expression and activation of the Akt-mTOR-p70S6K pathway in renal cell carcinoma (RCC), seeking to strengthen the rationale for targeted therapy of RCC using rapamycin or a rapamycin analogue. Tissue microarray sections containing 128 primary RCCs, 22 metastatic RCCs, and 24 non-neoplastic (normal) kidneys (NK) were immunostained with monoclonal antibodies to phosphorylated (p)-Akt (Ser473), p-mTOR (Ser2448), and p-p70S6K (Thr389). Western blotting was performed on 3 cases of clear cell RCC (CRCC) and the corresponding non-neoplastic (normal) renal tissues using the same antibodies. The immunostain scoring system included: (a) location; (b) distribution; and (c) intensity. The normal kidneys provided baseline scores for comparison. Expression of p-Akt, p-mTOR, and p-p70S6K was seen in 100% (n = 24) of NKs and nearly 100% (n = 150) of both primary and metastatic RCCs. The p-p70S6K was located in the nucleus in both NKs and RCCs. The p-Akt was observed in the nucleus and cytoplasm of NKs and in the nucleus and cytoplasm/ membrane (plasmalemma) of RCCs. The p-mTOR was identified in the membrane of NKs and the membrane/nucleus of RCCs. The levels of expression of p-p70S6K, p-mTOR, and p-Akt were significantly higher in RCC than in NK in the overall pattern (intensity and distribution, p &lt;0.05). Western blotting also showed higher expression of p-p70S6K, p-mTOR, and p-Akt in RCCs compared to the corresponding normal kidney tissues (p &lt;0.05). These findings indicate that correlative over-expression and activation of p-Akt, p-mTOR, and p-p70S6K are commonly observed in RCCs. After considering these findings in the context of other established protein circuitries and pathways in RCC, we propose therapeutic approaches that incorporate rapamycin-like agents and other small molecule inhibitors in a combinatorial fashion in future clinical trials for RCC.</description><identifier>ISSN: 0091-7370</identifier><identifier>PMID: 16951269</identifier><language>eng</language><publisher>United States</publisher><subject>Antineoplastic Agents - therapeutic use ; Carcinoma, Renal Cell - drug therapy ; Carcinoma, Renal Cell - metabolism ; Carcinoma, Renal Cell - pathology ; Humans ; Immunohistochemistry ; Kidney Neoplasms - drug therapy ; Kidney Neoplasms - metabolism ; Kidney Neoplasms - pathology ; Protein Array Analysis - methods ; Protein Kinases - drug effects ; Protein Kinases - metabolism ; Proto-Oncogene Proteins c-akt - metabolism ; Ribosomal Protein S6 Kinases, 70-kDa - metabolism ; Signal Transduction - drug effects ; Sirolimus - therapeutic use ; TOR Serine-Threonine Kinases ; Up-Regulation</subject><ispartof>Annals of clinical and laboratory science, 2006, Vol.36 (3), p.283-293</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16951269$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lin, Fan</creatorcontrib><creatorcontrib>Zhang, Ping L</creatorcontrib><creatorcontrib>Yang, Ximing J</creatorcontrib><creatorcontrib>Prichard, Jeffrey W</creatorcontrib><creatorcontrib>Lun, Mingyue</creatorcontrib><creatorcontrib>Brown, Robert E</creatorcontrib><title>Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas</title><title>Annals of clinical and laboratory science</title><addtitle>Ann Clin Lab Sci</addtitle><description>CCI-779 (temsirolimus), an ester of rapamycin and an inhibitor of the mammalian target of rapamycin (mTOR), is currently in phase II trials for treatment of patients with solid cancers. The mTOR functions as a checkpoint for cell proliferation, with upstream Akt and downstream p70S6K serving as its most important mediators. The aim of this study was to evaluate the expression and activation of the Akt-mTOR-p70S6K pathway in renal cell carcinoma (RCC), seeking to strengthen the rationale for targeted therapy of RCC using rapamycin or a rapamycin analogue. Tissue microarray sections containing 128 primary RCCs, 22 metastatic RCCs, and 24 non-neoplastic (normal) kidneys (NK) were immunostained with monoclonal antibodies to phosphorylated (p)-Akt (Ser473), p-mTOR (Ser2448), and p-p70S6K (Thr389). Western blotting was performed on 3 cases of clear cell RCC (CRCC) and the corresponding non-neoplastic (normal) renal tissues using the same antibodies. The immunostain scoring system included: (a) location; (b) distribution; and (c) intensity. The normal kidneys provided baseline scores for comparison. Expression of p-Akt, p-mTOR, and p-p70S6K was seen in 100% (n = 24) of NKs and nearly 100% (n = 150) of both primary and metastatic RCCs. The p-p70S6K was located in the nucleus in both NKs and RCCs. The p-Akt was observed in the nucleus and cytoplasm of NKs and in the nucleus and cytoplasm/ membrane (plasmalemma) of RCCs. The p-mTOR was identified in the membrane of NKs and the membrane/nucleus of RCCs. The levels of expression of p-p70S6K, p-mTOR, and p-Akt were significantly higher in RCC than in NK in the overall pattern (intensity and distribution, p &lt;0.05). Western blotting also showed higher expression of p-p70S6K, p-mTOR, and p-Akt in RCCs compared to the corresponding normal kidney tissues (p &lt;0.05). These findings indicate that correlative over-expression and activation of p-Akt, p-mTOR, and p-p70S6K are commonly observed in RCCs. After considering these findings in the context of other established protein circuitries and pathways in RCC, we propose therapeutic approaches that incorporate rapamycin-like agents and other small molecule inhibitors in a combinatorial fashion in future clinical trials for RCC.</description><subject>Antineoplastic Agents - therapeutic use</subject><subject>Carcinoma, Renal Cell - drug therapy</subject><subject>Carcinoma, Renal Cell - metabolism</subject><subject>Carcinoma, Renal Cell - pathology</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Kidney Neoplasms - drug therapy</subject><subject>Kidney Neoplasms - metabolism</subject><subject>Kidney Neoplasms - pathology</subject><subject>Protein Array Analysis - methods</subject><subject>Protein Kinases - drug effects</subject><subject>Protein Kinases - metabolism</subject><subject>Proto-Oncogene Proteins c-akt - metabolism</subject><subject>Ribosomal Protein S6 Kinases, 70-kDa - metabolism</subject><subject>Signal Transduction - drug effects</subject><subject>Sirolimus - therapeutic use</subject><subject>TOR Serine-Threonine Kinases</subject><subject>Up-Regulation</subject><issn>0091-7370</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kMtOwzAQRb0A0VL4BeQVu0i287KXqOIlFVVCZR2NnYkaFNvBdgr9ewKUzR3NnaPRzD0jS8YUz-q8ZgtyGeM7Y0IVBbsgC16pkotKLUl48WHc-zH4hN72hoJrqfUDmmmAQI13ZrYTuBSp7-Yp9QcM-DUGjBHbXxxM6g-Q5s7utq90hLT_hCPtHQ3oYKAGh1kgmN55C_GKnHcwRLw-1RV5e7jfrZ-yzfbxeX23yfYiVylrtaix5koJBIGdlMqA4QyQy0LmsuIgOw6KC8EML2WFBpXmWqAWCnXZ5ity-7d3fu5jwpga28efW8Chn2JTScnzWrIZvDmBk7bYNmPoLYRj859S_g1Sx2VK</recordid><startdate>2006</startdate><enddate>2006</enddate><creator>Lin, Fan</creator><creator>Zhang, Ping L</creator><creator>Yang, Ximing J</creator><creator>Prichard, Jeffrey W</creator><creator>Lun, Mingyue</creator><creator>Brown, Robert E</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>2006</creationdate><title>Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas</title><author>Lin, Fan ; Zhang, Ping L ; Yang, Ximing J ; Prichard, Jeffrey W ; Lun, Mingyue ; Brown, Robert E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h239t-db27e71992ea2ef889cac10ae18483861a8f1a91220c1586ece9b1b2eb29eb5d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Antineoplastic Agents - therapeutic use</topic><topic>Carcinoma, Renal Cell - drug therapy</topic><topic>Carcinoma, Renal Cell - metabolism</topic><topic>Carcinoma, Renal Cell - pathology</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Kidney Neoplasms - drug therapy</topic><topic>Kidney Neoplasms - metabolism</topic><topic>Kidney Neoplasms - pathology</topic><topic>Protein Array Analysis - methods</topic><topic>Protein Kinases - drug effects</topic><topic>Protein Kinases - metabolism</topic><topic>Proto-Oncogene Proteins c-akt - metabolism</topic><topic>Ribosomal Protein S6 Kinases, 70-kDa - metabolism</topic><topic>Signal Transduction - drug effects</topic><topic>Sirolimus - therapeutic use</topic><topic>TOR Serine-Threonine Kinases</topic><topic>Up-Regulation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lin, Fan</creatorcontrib><creatorcontrib>Zhang, Ping L</creatorcontrib><creatorcontrib>Yang, Ximing J</creatorcontrib><creatorcontrib>Prichard, Jeffrey W</creatorcontrib><creatorcontrib>Lun, Mingyue</creatorcontrib><creatorcontrib>Brown, Robert E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of clinical and laboratory science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lin, Fan</au><au>Zhang, Ping L</au><au>Yang, Ximing J</au><au>Prichard, Jeffrey W</au><au>Lun, Mingyue</au><au>Brown, Robert E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas</atitle><jtitle>Annals of clinical and laboratory science</jtitle><addtitle>Ann Clin Lab Sci</addtitle><date>2006</date><risdate>2006</risdate><volume>36</volume><issue>3</issue><spage>283</spage><epage>293</epage><pages>283-293</pages><issn>0091-7370</issn><abstract>CCI-779 (temsirolimus), an ester of rapamycin and an inhibitor of the mammalian target of rapamycin (mTOR), is currently in phase II trials for treatment of patients with solid cancers. The mTOR functions as a checkpoint for cell proliferation, with upstream Akt and downstream p70S6K serving as its most important mediators. The aim of this study was to evaluate the expression and activation of the Akt-mTOR-p70S6K pathway in renal cell carcinoma (RCC), seeking to strengthen the rationale for targeted therapy of RCC using rapamycin or a rapamycin analogue. Tissue microarray sections containing 128 primary RCCs, 22 metastatic RCCs, and 24 non-neoplastic (normal) kidneys (NK) were immunostained with monoclonal antibodies to phosphorylated (p)-Akt (Ser473), p-mTOR (Ser2448), and p-p70S6K (Thr389). Western blotting was performed on 3 cases of clear cell RCC (CRCC) and the corresponding non-neoplastic (normal) renal tissues using the same antibodies. The immunostain scoring system included: (a) location; (b) distribution; and (c) intensity. The normal kidneys provided baseline scores for comparison. Expression of p-Akt, p-mTOR, and p-p70S6K was seen in 100% (n = 24) of NKs and nearly 100% (n = 150) of both primary and metastatic RCCs. The p-p70S6K was located in the nucleus in both NKs and RCCs. The p-Akt was observed in the nucleus and cytoplasm of NKs and in the nucleus and cytoplasm/ membrane (plasmalemma) of RCCs. The p-mTOR was identified in the membrane of NKs and the membrane/nucleus of RCCs. The levels of expression of p-p70S6K, p-mTOR, and p-Akt were significantly higher in RCC than in NK in the overall pattern (intensity and distribution, p &lt;0.05). Western blotting also showed higher expression of p-p70S6K, p-mTOR, and p-Akt in RCCs compared to the corresponding normal kidney tissues (p &lt;0.05). These findings indicate that correlative over-expression and activation of p-Akt, p-mTOR, and p-p70S6K are commonly observed in RCCs. After considering these findings in the context of other established protein circuitries and pathways in RCC, we propose therapeutic approaches that incorporate rapamycin-like agents and other small molecule inhibitors in a combinatorial fashion in future clinical trials for RCC.</abstract><cop>United States</cop><pmid>16951269</pmid><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0091-7370
ispartof Annals of clinical and laboratory science, 2006, Vol.36 (3), p.283-293
issn 0091-7370
language eng
recordid cdi_proquest_miscellaneous_68813780
source MEDLINE; EZB-FREE-00999 freely available EZB journals; Journals@Ovid Complete
subjects Antineoplastic Agents - therapeutic use
Carcinoma, Renal Cell - drug therapy
Carcinoma, Renal Cell - metabolism
Carcinoma, Renal Cell - pathology
Humans
Immunohistochemistry
Kidney Neoplasms - drug therapy
Kidney Neoplasms - metabolism
Kidney Neoplasms - pathology
Protein Array Analysis - methods
Protein Kinases - drug effects
Protein Kinases - metabolism
Proto-Oncogene Proteins c-akt - metabolism
Ribosomal Protein S6 Kinases, 70-kDa - metabolism
Signal Transduction - drug effects
Sirolimus - therapeutic use
TOR Serine-Threonine Kinases
Up-Regulation
title Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T20%3A19%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Morphoproteomic%20and%20molecular%20concomitants%20of%20an%20overexpressed%20and%20activated%20mTOR%20pathway%20in%20renal%20cell%20carcinomas&rft.jtitle=Annals%20of%20clinical%20and%20laboratory%20science&rft.au=Lin,%20Fan&rft.date=2006&rft.volume=36&rft.issue=3&rft.spage=283&rft.epage=293&rft.pages=283-293&rft.issn=0091-7370&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E68813780%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68813780&rft_id=info:pmid/16951269&rfr_iscdi=true